Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which … Read more
Telix Pharmaceuticals Limited (TLX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.084x
Based on the latest financial reports, Telix Pharmaceuticals Limited (TLX) has a cash flow conversion efficiency ratio of -0.084x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-52.55 Million) by net assets ($622.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Telix Pharmaceuticals Limited - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Telix Pharmaceuticals Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Telix Pharmaceuticals Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Telix Pharmaceuticals Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mineral Res
PINK:MALRY
|
0.205x |
|
Kokuyo Co., Ltd.
PINK:KUKYF
|
0.073x |
|
Acushnet Holdings Corp
NYSE:GOLF
|
0.190x |
|
Alupar Investimento SA
SA:ALUP11
|
0.039x |
|
Frasers Centrepoint Trust
PINK:FRZCF
|
0.014x |
|
Digitalbridge Group Inc
NYSE:DBRG
|
0.031x |
|
Optowide Technologies Co. Ltd. A
SHG:688195
|
N/A |
|
Operadora de Sites Mexicanos S.A. de C.V
PINK:OPMXF
|
0.037x |
Annual Cash Flow Conversion Efficiency for Telix Pharmaceuticals Limited (2011–2025)
The table below shows the annual cash flow conversion efficiency of Telix Pharmaceuticals Limited from 2011 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $622.27 Million | $-25.93 Million | -0.042x | -155.03% |
| 2024-12-31 | $568.21 Million | $43.03 Million | 0.076x | -52.79% |
| 2023-12-31 | $148.91 Million | $23.88 Million | 0.160x | +121.37% |
| 2022-12-31 | $85.25 Million | $-63.97 Million | -0.750x | +95.39% |
| 2021-12-31 | $3.64 Million | $-59.33 Million | -16.290x | -65771.77% |
| 2020-12-31 | $79.02 Million | $1.96 Million | 0.025x | +107.52% |
| 2019-12-31 | $70.73 Million | $-23.33 Million | -0.330x | +15.89% |
| 2018-12-31 | $52.90 Million | $-20.75 Million | -0.392x | -220.53% |
| 2017-12-31 | $49.29 Million | $-6.03 Million | -0.122x | -120.22% |
| 2016-12-31 | $-1.77 Million | $-1.07 Million | 0.605x | -96.31% |
| 2015-12-31 | $-213.93K | $-3.51 Million | 16.417x | +1796.50% |
| 2014-12-31 | $-2.17 Million | $-1.88 Million | 0.866x | +208.01% |
| 2013-12-31 | $1.50 Million | $-1.21 Million | -0.801x | -1850.44% |
| 2011-12-31 | $-11.46 Million | $-524.76K | 0.046x | -- |